Synergistic effects of cannabidiol and cytokine-induced killer cells via the modulation of TRPV2 channel and intracellular p-ERK 1/2 expression on non-small cell lung cancer cells

Author:

Li Yutao1,Sharma Amit1,Hoffmann Michèle J.2,Skowasch Dirk1,Essler Markus1,Schmidt-Wolf Ingo G. H.

Affiliation:

1. University Hospital Bonn

2. Heinrich Heine University Düsseldorf

Abstract

Abstract A multitude of findings from the cell cultures and animal studies are available to support the anti-cancer properties of cannabinoids cannabidiol (CBD). Since CBD acts on multiple molecular targets, its clinical adaptation, especially in combination with cancer immunotherapy regimen remains a serious concern. Considering this, herein, we extensively studied the effect of CBD on the cytokine-induced killer (CIK) cells immunotherapy approach using multiple non-small cell lung cancer (NSCLC) cells harboring diverse genotypes. Our analysis showed that, a) CB2 receptor surface and intracellular expression increased significantly in NSCLC cells following co-culture with CIK cells, b) CBD exerts a pronounced synergistic effect on CIK-mediated lysis, resulting in a substantial increase in IFN-γ production, c) CBD explicitly promotes the CD25+CD69+ population and CD62LCD45RA+ terminal effector memory (EMRA) population in NKT-CIK cells, suggesting an activation and effector memory T-cell differentiation. Of interest, we observed that clinically relevant CBD concentrations enhanced the calcium influx (mediated by the TRPV2 channel) and p-ERK expression directly in CIK cells, while in cancer cells it induced DNA double-strand breaks via upregulation of histone H2AX phosphorylation. Notably, the migration and invasion ability of NSCLC cells suppressed by CBD (in the absence of CIK cells) was rescued using the TRPV2 antagonist (Tranilast). We further investigated the epigenetic effects of this synergy and found that combining CBD with CIK cells decreased the LINE-1 mRNA expression and the global DNA methylation level in NSCLC cells carrying KRAS mutation. Taken together, CBD holds a great potential for treating NSCLC with CIK cell immunotherapy and its complete success requires careful consideration of the patients' genetic background.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3